The researchers viewed the result on the yeast of 21 peptides which had either; cell-penetrating or antimicrobial properties. Cell-penetrating peptides tend to be investigated as medication delivery vectors and are in a position to cross the cell membrane, although the exact mechanism for this is unknown. Antimicrobial peptides, on the other hand, are organic antibiotics and destroy many types of microbe including some bacteria, fungi and viruses. Tina Holm and her colleagues at Stockholm University and Karolinska Institute, added these different peptides types to separate yeast colonies and assessed the toxicity of every peptide type to the yeast. They found that six of the 21 peptides they tested effectively killed the yeast without damaging the membrane of keratinocytes, human pores and skin cells.Announced today that its first malignancy therapeutic drug candidate removed all intraperitoneal ovarian malignancy tumors in a pre-clinical study tests a novel treatment regimen. Funded by the National Malignancy Institute through the business's initial NCI grant awarded December last year, its lead candidate medication Vicrostatin was coupled with a drug-eluting gel and applied in to the peritoneum for sustained discharge of the drug right to ovarian tumor metastatic tumors. Chen, MD, Ph.D., the company's Chief Medical Officer, and suggest an equivalent individual treatment for ovarian cancers patients is feasible. This approach is definitely early but if we are able to achieve comparable results in human clinical trials with women suffering from ovarian cancer this treatment could significantly change the current standard of treatment.